The study of RUNX3 in tumor pathogenesis is a rapidly expanding area of cancer research. Functional inactivation of RUNX3-through mutation, epigenetic silencing, or cytoplasmic mislocalization-is frequently observed in solid tumors of diverse origins. This alone indicates that RUNX3 inactivation is a major risk factor in tumorigenesis and that it occurs early during progression to malignancy. Conversely, RUNX3 has also been described to have an oncogenic function in a subset of tumors. Although the mechanism of how RUNX3 switches from tumor suppressive to oncogenic activity is unclear, this is of clinical relevance with implications for cancer detection and prognosis. Recent developments have significantly contributed to our understanding of the pleiotropic tumor suppressive properties of RUNX3 that regulate major signaling pathways. This review summarizes the important findings that link RUNX3 to tumor suppression.
Introduction

RUNX family of transcription factors
The Runt-related transcription factors (RUNX) describe a family of evolutionarily conserved metazoan proteins, which share the highly homologous N-terminal Runt domain, a DNA-binding, and heterodimerization region of about 120 amino acids. Initially discovered as a heterodimeric protein complex comprising RUNX and cofactor PEBP2b/CBFb 20 years ago, RUNX proteins are rapidly gaining prominence as major players in cancer pathogenesis. In mammals, three RUNX family members have been identified. The RUNX genes are widely expressed, but show differential, tissue-specific expression. Although their strong homology indicates a certain degree of redundancy as observed during mouse embryogenesis (Fukushima-Nakase et al., 2005) and transcription regulation of various genes (for example Sgpp1, Ncam1, p21 WAF1 ) (Wotton et al., 2008) , the RUNX proteins have been shown to perform distinct functions that are dependent on tissue type ). This review explores the dualistic associations of RUNX3 with cancer with emphasis on the emerging concept of RUNX3 as a multifunctional suppressor of solid tumors.
RUNX3 inactivation is prevalent in solid tumors
Hemizygous deletion of RUNX3 gene The location of RUNX3 at chromosome 1p36, a deletion hotspot in diverse cancers of epithelial, hematopoietic, and neural origins (Bagchi and Mills, 2008) , prompts the following questions: How often is RUNX3 deleted? Does RUNX3 deletion confer any cancer growth advantage? Examination of gastric cancer tissue specimens revealed hemizygous deletions of RUNX3 at frequencies which increased with tumor grade (Li et al., 2002) . Likewise, RUNX3 hemizygous deletion and concomitant decrease in RUNX3 expression are also prevalent in gastric, bile duct, pancreatic, and lung cancer cell lines (Li et al., 2002; Wada et al., 2004; Yanada et al., 2005) . This suggests that downregulation of RUNX3 expression is an early occurrence during progression to malignancy, and thus, provides a strong hint of RUNX3 tumor suppressive function. Moreover, it is noteworthy that genes mapping to human 1p36 show syntenic conservation with mouse chromosome 4, lending weight to the theory that this region harbors a cluster of tumor suppressor genes, which work cooperatively and when deleted would drive tumorigenesis (Bagchi and Mills, 2008) . The 1p36 tumor suppressor genes include retinoblastoma protein-interacting zincfinger (RIZ)1, chromodomain helicase DNA-binding protein 5 (CHD5), secretory phospholipase PLA2G2A (Modifier of Min-1) (Cormier et al., 1997) , and TP73. Interestingly, RIZ1, also known as PRDM2, is a member of the nuclear histone/protein methyltransferase superfamily that methylates histone 3 Lys 9 (H3K9) residues, whereas CHD5 belongs to the SWI/SNF chromatin modifier family. As with all RUNX family members, RUNX3 encodes a highly conserved C-terminus motif VWRPY that was shown to bind co-repressor proteins TLE1 and Sin3A, which in turn recruit histone deacetylase (Stifani et al., 1992; Aronson et al., 1997; Imai et al., 1998; Levanon et al., 1998) .
As part of this multiprotein complex, RUNX3 can repress gene transcription through modulation of chromatin structure. It is tempting, therefore, to speculate that collaboration of RUNX3 with these other 1p36 chromatin modifiers suppresses transcription that contributes to tumor development.
Epigenetic silencing of RUNX3
In tumor cells, mutation of one allele of a gene is frequently accompanied by hypermethylation of the other allele, resulting in complete functional inactivation of the gene (Jones and Baylin, 2002) . Besides deletion of the RUNX3 gene, recent years have seen a surge in reports of other modes of RUNX3 inactivation-be it through promoter hypermethylation or protein mislocalization-in solid tumor tissues. To date, hypermethylation of the CpG island at the RUNX3 promoter is one of the most common aberrant methylation events in cancer, suggesting that RUNX3 inactivation is a significant risk factor for tumorigenesis. Diverse tumor tissues have been reported to exhibit RUNX3 hypermethylation and inactivation. These include tissues and cell lines that originated from gastric (Li et al., 2002; Oshimo et al., 2004) , bladder (Kim et al., 2005; Wolff et al., 2008) , colorectal (Ahlquist et al., 2008; Soong et al., 2009; Subramaniam et al., 2009) , breast (Lau et al., 2006; Jiang et al., 2008) , lung (Sato et al., 2006) , pancreatic (Wada et al., 2004 ), brain cancers (Mueller et al., 2007) , and hepatocellular carcinoma . Notably, RUNX3 methylation status is one of the five markers used to classify colorectal tumors associated with very high frequencies of CpG island methylation (CIMP), microsatellite instability, and BRAF mutation (Weisenberger et al., 2006) . Moreover, hypermethylation of RUNX3 is associated with a 100-fold increase risk of developing bladder cancer (Kim et al., 2005) . RUNX3 methylation is not only acquired early during tumorigenesis, but also increases with age: RUNX3 is thus an attractive candidate for cancer detection and prognosis (Wolff et al., 2008) .
Conversely, RUNX3 overexpression correlates with reduced invasive potential of breast cancer cells . Similarly, RUNX3 expression in the breast stroma is associated with reduced rate of recurrence, and thus, a good clinical outcome in breast cancer (Finak et al., 2008) . Furthermore, the presence of nuclear RUNX3 protein in esophageal squamous cell carcinomas correlates with increased sensitivity to radiotherapy, whereas RUNX3 inactivation is linked to radioresistance and poor prognosis (Sakakura et al., 2007) .
Putative causes of RUNX3 hypermethylation
Although it is unclear what causes aberrant methylation of RUNX3, RUNX3 was recently reported to be silenced in gastric, breast, prostate, colon, and pancreatic cancer cell lines by another epigenetic mechanism-enhancer of Zeste Homologue 2 (EZH2)-mediated histone methylation (Fujii et al., 2008) . The EZH2 oncogene is a component of Polycomb-repressor complex 2, which is required for stem cell pluripotency and self-renewal. It is targeted to gene promoters of important developmental regulators, including RUNX3 , in which it methylates histone H3 at the Lys27 (H3K27) residue to repress transcription. Interestingly, EZH2 can direct DNA methylation by recruitment of DNMTs to target gene promoters, suggesting that it may be a significant causative factor of aberrant methylation in cancer (Vire et al., 2006) . In addition, H3K27 methylation has been shown to mark genes for de novo methylation in cancer (Schlesinger et al., 2007) . A recent study found that frequent overexpression of EZH2 in aggressive solid tumors is largely due to the loss of its regulator microRNA-101 (Varambally et al., 2008) . More specifically, reintroduction of miR-101 or knockdown of EZH2 expression was sufficient to reduce H3K27 trimethylation and increase RUNX3 mRNA levels. In the same vein, Fujii et al. (2008) found that EZH2 binds to the RUNX3 promoter, resulting in upregulation of H3K27 methylation and concomitant downregulation of RUNX3 expression (Fujii et al., 2008) . Recently, Lee et al. (2009) extended this finding by showing that hypoxia-induced upregulation of G9a histone methyltransferase and HDAC1 expression also cause epigenetic RUNX3 silencing through H3K9 methylation and decreased H3 acetylation at RUNX3 promoter. As hypoxia is commonly associated with solid tumors of 41 mm 3 , this suggests that RUNX3 inactivation may be associated with increased tumor size . Helicobacter pylori, a major causative factor of gastric cancer, was also reported to alter RUNX3 methylation status through enhanced production of nitric oxide in macrophages (Katayama et al., 2009) . Moreover, the same group showed that lipopolysaccharide can also induce methylation changes, again through nitric oxide production, suggesting that inflammation may be another cause of RUNX3 hypermethylation in gastric cancer. Estrogen exposure is an important risk factor in breast cancer pathogenesis. It induces neoplastic transformation in epithelial cells that were derived from mammospheres isolated from healthy breast tissues. Interestingly, exposure of these mammosphere-derived cells to estrogen was sufficient to induce hypermethylation of RUNX3 (Cheng et al., 2008) . All in all, these are clear indications that contextual cues from growth factors and environmental stimuli give rise to aberrant epigenetic silencing of RUNX3 in cancer cells (see Figure 1 ).
Cytoplasmic sequestration of RUNX3
Not only is epigenetic silencing of RUNX3 a frequent occurrence in cancer, cytoplasmic sequestration of RUNX3 was reported in a significant proportion of cancer cases-about 15% of colorectal cancer , 80% of breast cancer (Lau et al., 2006) , 38% of gastric cancer , and oral squamous cell carcinomas (Gao et al., 2009) . Moreover, RUNX3 cytoplasmic mislocalization is associated with advanced colorectal tumor stages, whereas nuclear RUNX3 expression was correlated with better patient prognosis . Likewise, enforced cytoplasmic localization of RUNX3 is associated with increased tumorigenic potential of gastric epithelial cells on engraftment onto nude mice . Collectively, these findings indicate that nuclear RUNX3 and its downstream transcriptional targets are crucial for tumor suppression. Sequestration of tumor suppressor proteins in subcellular locations where they cannot exercise their function is a frequent occurrence in cancer cells. Examples include well-established tumor suppressors such as p27 KIP , BRCA1, and pRb1. As no mutation has been found in the coding sequence of the mislocalized RUNX3, the reasons for cytoplasmic compartmentalization of RUNX3 is likely to be posttranslational modification or intracellular environment.
However, it should be noted that RUNX3 cytoplasmic localization is not limited to cancer cells as a large proportion of chief cells from normal stomach and colon epithelia show cytoplasmic localization of RUNX3. Thus, elucidating this intrinsic ability of RUNX3 to shuttle between nuclear and cytoplasm compartments may offer insights as to how nuclear translocation of RUNX3 may be induced for cancer therapy.
Mechanisms underlying cytoplasmic translocation of RUNX3
Interestingly, ectopic expression of a C-terminal truncation of RUNX3 in SNU16 gastric cancer cells resulted in both nuclear exclusion of the exogenous RUNX3 (1-187aa) deletion mutant and the endogenous wildtype RUNX3 , suggesting that the C-terminal domain is necessary for nuclear localization of RUNX3. Nuclear exclusion of RUNX proteins can be accommodated by decreasing microtubule-dependent nuclear import, reducing nuclear retention by loss of association with chromatin-related macromolecular complexes or inhibiting nuclear export (Pockwinse et al., 2006; Pande et al., 2009) . Moreover, activation of TGF-b pathway triggered nuclear translocation of endogenous RUNX3 in SNU16 cells and this subsequently led to growth inhibition . With the TGF-b pathway frequently impaired in cancer tissues, this would mean frequent cytoplasmic sequestration and, thus, functional inactivation of RUNX3. It is not known how TGF-b elicits nuclear translocation of RUNX3. However, because SMAD and RUNX3 proteins interact (Hanai et al., 1999) , it is possible that perturbation of Smad nuclear import/export may promote cytoplasmic accumulation (Inman et al., 2002) . Alternatively, a clue can be gleaned from the report that TGF-b stimulates acetylation of RUNX3 protein by p300 and that this inhibits RUNX3 ubiquitination by Smurf1, leading to the stabilization of RUNX3 protein (Jin et al., 2004) . It remains to be seen whether acetylated RUNX3 is more efficiently retained in the nucleus. Aside from acetylation, RUNX3 protein can be phosphorylated by the putative oncoprotein, Pim-1 serine/threonine kinase (Aho et al., 2006) , and this induces nuclear exclusion of RUNX3 (Kim et al., 2008) . Furthermore, Jun-activation domain-binding protein 1 (Jab1/CSN5) promotes nuclear export and degradation of RUNX3 through CSN (component of the COP9 signalosome)-associated kinase activities . Curiously, hypoxic culture conditions are also associated with cytoplasmic retention of RUNX3 in a G9a and HDAC1-dependent manner. Consistent with this observation, overexpression of G9a and HDAC1 prevented nuclear translocation of RUNX3 
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ubiquitination of RUNX3, resulting in its cytoplasmic translocation and degradation (Chi et al., 2009) . Src kinase phosphorylates tyrosine residues in RUNX3, and overexpression of activated Src correlates with RUNX3 cytoplasmic localization (Goh et al., 2010) . Collectively, these data indicate that aberrant signals from oncogenic pathways may mediate post-translational modification and subsequent cytoplasmic mislocalization of RUNX3 in cancer cells.
Insertional mutagenesis screen implicates RUNX3 in tumor development
Several independent research groups have uncovered strong links between RUNX3 and cancer potentiation through insertional mutagenesis-based genetic screens. It should be emphasized, however, that these screens preferentially identify oncogenes and that among the Runx family, Runx2 is most commonly reported (Cameron et al., 2003) . An early indication of Runx3's involvement came from a study involving Moloney murine leukemia virus infection of CD2-MYC transgenic mice (Stewart et al., 2002) . The CD2-MYC mice selectively express the c-MYC oncogene in T cells. Although uninfected mice develop tumors infrequently, murine leukemia virus infection at birth accelerates tumor onset: all infected mice succumb to thymic lymphomas by 80 days (Stewart et al., 1996) . After screening the viral-induced thymic lymphomas, a proviral integration site was uncovered 30 kb upstream of the Runx3 distal P1 promoter. This resulted in a significant increase in the expression of Runx3 P1 (distal) isoforms in the pertinent lymphoma. As the only Runx protein expressed in this lymphoma, Runx3 thus seems to synergize with MYC oncogene to promote lymphomagenesis (Stewart et al., 2002) . Miething et al. (2007) further explored RUNX3's cancer function in leukemia when they incorporated a drug used for treatment of Bcr-Abl-expressing leukemia, imatinib, in their retroviral mutagenesis screen-they showed that insertion of a retroviral element in the vicinity of the RUNX3 promoter results in elevated RUNX3, which in turn led to increased resistance to imatinib-induced apoptosis and thus chronic myeloid leukemia (Miething et al., 2007) . Runx3 was also identified as a cancerassociated gene by Sleeping Beauty transposable elements-transposon integration at the 5 0 position of the RUNX3 gene was associated with T-cell lymphoma (Dupuy et al., 2005) and prostate cancer (Rahrmann et al., 2009) . The non-viral Sleeping Beauty insertional mutagen thus offers a marked advantage over the retroviral system, which is limited to identifying cancer genes in hematopoietic tumors: Sleeping Beauty screens can be adapted for epithelial cancers. This raises several interesting questions. How does this relate to other cancers of epithelial origins in which RUNX3 functions as tumor suppressor? Furthermore, as progenitor cancer stem cells are implicated in cancer persistence, does ectopic expression of RUNX3 influence the response of cancer stem cells to drug therapy?
Altogether, these findings suggest that while RUNX3 inactivation is a major determinant of cancer pathogenesis (see Table 1 ) and clinical outcome in many cancer types, in certain tumor types, overexpression of RUNX3 is oncogenic. In other words, RUNX3 mediates context-dependent tumor suppression.
Molecular mechanisms that underlie RUNX3's anti-tumor properties
Runx3 knockout mice are prone to gastrointestinal cancer Although these different experimental approaches led to the same conclusion-that of RUNX3's involvement in cancer-they do not directly prove that RUNX3 is a tumor suppressor in epithelial cells. In 2002, this concept was rigorously tested using Runx3 knockout mice (Li et al., 2002) . Runx3 À/À mice exhibited hyperplasia of the gastric mucosa. The increased proliferation rate in the gastric epithelia of Runx3 À/À mice was attributed to suppression of apoptosis and reduced sensitivity to the growth inhibitory effects of TGF-b1. RUNX3 deficiency, thus, corresponded with compromised TGF-b signaling. Earlier shown to bind directly to TGF-b signaling effector SMAD3 for synergistic induction of Immunoglobulin germline C a promoter (Shi and Stavnezer, 1998; Hanai et al., 1999) during Immunoglogulin A class switching, RUNX3 is now also known to have a function in TGF-b-induced growth inhibition. After stimulation by TGF-b cytokines, RUNX3 cooperates with SMAD proteins to directly upregulate transcription of the proapoptotic gene Bim1 and increase expression of the cyclin-dependent kinase inhibitor p21 WAF1 in gastric cancer cells (Chi et al., 2005; Yano et al., 2006) . Moreover, the ability of RUNX3 to target SMADs to distinct nuclear foci on stimulation by TGF-b further strengthens the case for RUNX3 as a regulator of the TGF-b signaling pathway (Zaidi et al., 2002) .
The detection of Runx3 in the epithelial cells of small and large intestines in mice hinted that RUNX3 may also function as a tumor suppressor in the intestinal epithelium. Indeed, the intestinal epithelia of Runx3 À/À mice exhibit hyperplasia that is associated with robust proliferation . Further examination revealed that this phenomenon is the likely consequence of enhanced Wnt signaling activity and transcriptional upregulation of Wnt target genes such as c-Myc and cyclinD1. RUNX3 was further found to form a ternary complex with key Wnt effectors TCF4 and b-catenin with the resulting complex showing reduced ability to bind DNA and activate transcription of Wnt target genes. RUNX3, therefore, antagonizes aberrant Wnt signaling, which, substantial evidence have shown, provides an oncogenic impetus to sustain colorectal cancer growth.
The Adenomatous Polyposis Coli (APC) gene is a well-known gatekeeper of colorectal tumorigenesis. To compare RUNX3's tumor suppressive capabilities against that of APC, Runx3 þ /À mice were bred in parallel with Apc Min/ þ mice on the same BALB/c background. After a relatively long latency of about 65 weeks of age, 54% of the Runx3 þ /À mice develop small intestinal adenomas, a frequency comparable with that of Apc Min/ þ mice (64%) . Tumors isolated from both mice displayed similar phenotypesupregulation of cyclin D1 and c-Myc, downregulation of p21
WAF1
-indicating increased activity of TCF4-bcatenin complex. Interestingly, unlike Apc Min/ þ mice in which biallelic loss of Apc occurs, the Apc locus was completely normal in Runx3 þ /À mice which exhibited no nuclear accumulation of oncogenic b-catenin. The fact that RUNX3 deficiency promotes adenoma formation independent of APC inactivation indicates that RUNX3 is a gatekeeper in its own right.
Curiously, unlike Runx3 þ /À mice, Runx3 À/À mice did not develop epithelial tumors. Although this is an unusual characteristic for a tumor suppressor gene, there is a precedent: working with tumor suppressor Pten knockout mice, Pandolfi and co-workers observed that although the loss of one allele of Pten is associated with accelerated growth, the loss of both Pten alleles resulted instead in reduced proliferation, which stems from cellular senescence (Chen et al., 2005) . Pandolfi suggested that biallelic inactivation of the Pten tumor suppressor elicits a strong oncogenic stimulus that sets off a p53-mediated fail-safe mechanism to induce senescence.
It is commonly accepted that progression from adenoma to carcinoma would require further inappropriate inputs from other signaling networks. In colorectal cancer, frequent mutations in various components of the TGF-b pathway impair the ability of cancer cells to undergo TGF-b-induced apoptosis. The ability of RUNX3 to regulate both Wnt and TGF-b signaling pathways suggests that RUNX3 may orchestrate tumor suppression in a three-way crosstalk.
The isolation of the R122C mutation in RUNX3 from a gastric cancer patient was an important milestonethis mutation confirms that dysfunctional RUNX3 can indeed contribute to human tumor formation. The relevance of this mutation is underscored by the discovery of a mutation (R169Q) at the equivalent position in RUNX2 from a patient with the skeletal disorder cleidocranial dysplasia (Zhou et al., 1999) . Notably, tumorigenicity of MKN28 gastric cancerderived cell line is strongly inhibited by exogenous expression of RUNX3. Exogenous expression of R122C not only failed to inhibit tumor growth in nude mice but instead, induced larger tumors than the parental cell line, suggesting that this single amino-acid substitution in the DNA-binding Runt domain was sufficient to confer an oncogenic function on Runx3 (Li et al., 2002) . This seems to stem from multiple defects in its protein properties. The R122C mutant has reduced affinity for DNA with the consensus RUNX-binding site; it is also less efficient in binding SMADs (Chi et al., 2005) . The combination of these defects results in impaired participation in TGF-b signaling, as seen by reduced activation of p21 WAF1 promoter during TGF-b stimulation (Chi et al., 2005) . More recently, we found that the R122C mutant is defective in binding to the TCF4 transcription factor (Ito et al., submitted) , suggesting that this mutation enhances tumor growth because it impinges on the tumor suppressive functions of RUNX3 in both Wnt and TGF-b signaling pathways during various stages of tumor progression. Besides gastric cancer, mutations affecting the Runt domain of RUNX3 as well as RUNX3 polymorphisms have also been isolated from bladder cancer tissues (Kim et al., 2005; Zhang et al., 2008) , suggesting that such mutations or genetic variations may drive tumorigenesis.
It is noteworthy that both Wnt and TGF-b signaling pathways are also involved in the induction of epithelialmesenchymal transition (EMT) during embryonic development (Thiery and Sleeman, 2006) . EMT is a complex developmental process in which epithelial cells attain the migratory properties of mesenchymal cells through the loss of cell-cell or cell-matrix adhesion. Recently, the induction of EMT has been increasingly linked to cancer invasion and metastasis. Transcription repressors Snail and Slug are believed to have important functions in initiating the pathological EMT process. On oncogenic stimulation, they directly repress transcription of adherens-junction protein E-cadherin (Batlle et al., 2000; Cano et al., 2000) and tight-junction protein claudin-1 (Martinez- Estrada et al., 2006) , facilitating loss of cell adhesion. Another inducer of EMT during malignant progression is TGF-b signaling, which results in the dissolution of tight junctions. This ability of TGF-b to induce EMT presents an interesting paradox that is opposite of its tumor suppressive function. We found recently that claudin-1 is a direct and positive target of Runx3 and that Runx3 À/À -derived gastric epithelial cells have reduced levels of claudin-1 and increased tumorigenic potential when compared with the Runx3 þ / þ cells. This is partly because Runx3 cooperates with TGF-b effectors Smads to directly upregulate claudin-1 transcription (Chang et al., 2010) . As the expression of claudin-1 inhibits proliferation in gastric cancer cells, these findings present another mechanism underlying RUNX3's tumor suppressive effects and invite speculation on the function of RUNX3 during later stages of cancer. Whether RUNX3 affects the abilities of TGF-b and Wnt to induce EMT remain unknown.
Another way of explaining the oncogenicity of EMT is the ability of epithelial cells, but not mesenchymal cells, to undergo anoikis, an apoptotic process induced by cell detachment from the extracellular matrix. Anoikis is, therefore, an important mechanism to prevent metastasis. EMT processes promote anoikisresistance, thus permitting tumorigenesis. The ability of RUNX3 to repress transcription of neutrophin receptor TRKB during neuronal fate determination (Inoue et al., 2007) has important implications for RUNX3's function in EMT, considering that TRKB is a potent oncogene that suppresses anoikis (Douma et al., 2004; Geiger and Peeper, 2007) . TRKB is highly expressed in neuroblastoma as well as aggressive tumors of pancreatic, prostate, and lymphoid origins. Ectopic expression of TRKB was sufficient to confer anoikis resistance and convert nonmalignant cells into highly tumorigenic cells. Induction of EMT is likely to coincide with reduction of RUNX3 expression, followed by subsequent downregulation of claudin-1, upregulation of TRKB, and suppression of anoikis. It is probable that RUNX3 represses TRKB transcription to promote anoikis and suppress metastatic spread of cancer cells.
Closely linked to EMT and the theme of progenitor cell renewal is another exciting, but less well-defined concept-the function of cancer stem cells. EMT induction of transformed mammary epithelial cells leads to enrichment of cancer stem cells . Together with the report that increased RUNX3 expression is associated with cancer persistence in CML (Miething et al., 2007) , it may be that RUNX3 is involved in cancer stem cell growth through modulation of EMT processes. Moreover, these findings point to the possibility that RUNX3 not only functions as a tumor suppressor during early tumor development, but may affect late stages of cancer progression.
Controversy on Runx3 expression in gastrointestinal tract epithelia
It should be noted, however, that Groner and coworkers reported conflicting data: they could not detect Runx3 in the mouse gastrointestinal tract (GIT) epithelium (Brenner et al., 2004) . We have earlier found that RUNX3 mRNA transcripts in GIT are relatively low compared with peripheral blood . Moreover, RUNX3 was recently shown to interact with MDM2, which mediates ubiquitinylation and proteolytic degradation of RUNX3 (Chi et al., 2009) . MDM2 is one of the E3 ligases in the ubiquitin-proteasome system and is known to ubiquitinate and degrade p53 tumor suppressor. Owing to this, the amount of p53 is known to be quite low in normal cells (Ashcroft and Vousden, 1999) . It is thus likely that the already low expression level of Runx3 in GIT epithelium is further reduced because of MDM2-mediated degradation. Failure to detect Runx3 expression in GIT, as reported by Groner's group, may stem from the low amounts of Runx3 expressed in GIT epithelium and relative sensitivity of various methods used for detection.
The concept that inflammation promotes tumor development has steadily gained prominence in the recent years (Coussens and Werb, 2002) . For example, overexpression of a pro-inflammatory cytokine interleukin 1b in the gastric epithelium was sufficient to induce inflammation and hyperplasia (Tu et al., 2008) . Consistent with this notion, Groner's group attributed the GIT hyperplasia exhibited by their Runx3 knockout mice to inflammatory bowel disease caused by Runx3 deficiency in leukocytes in the GIT (Brenner et al., 2004; Levanon and Groner, 2009 ), as they could not detect Runx3 expression in the GIT epithelium of wildtype mice. In contrast, however, the knockout mice generated by Ito et al. (2008) exhibited minimal inflammation and as such was unlikely to cause hyperplasia in the GIT epithelium. Moreover, when bone marrow cells of Runx3 À/À mice were transplanted into irradiated wildtype mice, these mice with Runx3 À/À leukocytes and wildtype epithelial cells neither exhibit significant inflammation nor develop hyperplasia, further confirming that loss of Runx3 in epithelial cells led to acquisition of tumorigenic potential in GIT . The varying degrees of inflammation induced in mice from the two laboratories may be caused by variations in the conditions of the mouse facilities.
Although the studies by Ito et al. (2008) suggest that hyperplasia of GIT in Runx3 À/À mice is epithelial cell autonomous, the function of inflammation cannot be ignored. Runx3 is necessary for proper T-cell development and it is possible that both Runx3 À/À leukocytes and epithelial cells contribute toward malignancy.
As the opposing viewpoints have already been discussed elsewhere, the reader is advised to refer to the respective publications (Bae and Ito, 2003; Levanon et al., 2003; Ito et al., 2009; Levanon and Groner, 2009) . We anticipate that this controversy will soon be resolved with further in-depth studies.
RUNX3 has putative functions in other cancer signaling pathways
The interaction of RUNX3 and putative oncoprotein yes-associated protein (YAP) through their PY motif and WW domain, respectively, offers another perspective (Yagi et al., 1999 ). RUNX3's recruitment of YAP transcription co-activator results in enhanced target promoter activation. More recently, YAP was found to be a component of the Hippo pathway, which regulates organ size through modulation of proliferative and apoptotic activities. YAP expression is frequently increased in cancer, and inactivation of YAP by the Hippo pathway leads to reduced cell contact inhibition (Zhao et al., 2007) . As mutation of the WW domain in YAP impairs its ability to promote cell proliferation and oncogenic transformation (Zhao et al., 2009) , it remains to be seen whether RUNX3 affects YAP tumor promoting activities through interaction with its WW domain.
The fact that RUNX3 physically interacts with Forkhead box O3a (FOXO3a) tumor suppressor protein at the proapoptotic gene Bim promoter to promote transcription and apoptosis (Yamamura et al., 2006) prompts speculation of functions for RUNX3 in other Foxo3A-related activities, and these include regulation of intestinal inflammation (Snoeks et al., 2009) , AKT oncogenic signaling pathway, response to oxidative stress (Brunet et al., 2004) , as well as activation of ATM during DNA damage . Interestingly, FOXOs protects hematopoietic stem cells from oxidative stress and is thus necessary for long-term maintenance of hematopoietic stem cells in the progenitor compartment (Tothova and Gilliland, 2007; . Taken together with the recent report that resistance to reactive oxygen species is a characteristic of breast cancer stem cells (Diehn et al., 2009) , it is worthwhile to investigate whether RUNX3 affects FOXO activity during cancer stem cell formation.
RUNX3 in DNA repair
It is well accepted that DNA damage promotes cancer progression through genetic alterations of components in cell signaling pathways, cell cycle regulation, repair, and apoptotic processes. Certainly, dysfunctional repair mechanisms are associated with high cancer risks. Recent reports have linked RUNX3 with various DNA repair machineries. Mutations in components of DNA mismatch repair are extremely frequent in colorectal cancer cells. In particular, deficiencies in MLH3 and PMS2 accelerate tumor progression. Against this mismatch deficient background, overexpression of Transducin enhancer of Split (Tle) family gene, Tle6-like, further enhances tumor progression. The direct interaction of RUNX3 with Tle6 results in attenuation of RUNX3 transactivation abilities (Chen et al., 2008) . Aside from mismatch repair, Runx3 was found to interact with DNA repair protein Ku70 (Tanaka et al., 2007) , a component of the major repair mechanism for double-strand DNA breaks, the non-homologous end-joining repair. The report detailing the interaction of RUNX3 and MDM2 at the Runt domain (see above) provides another interesting viewpoint that RUNX3, in addition to p53, is negatively regulated by p14 ARF -MDM2 surveillance pathway in response to aberrant Ras oncogene activation (Chi et al., 2009 ).
RUNX3 as a mediator of oncogene-induced senescence
Oncogene-induced senescence is a well-known characteristic of early preneoplastic lesions. Triggered by oncogenes such as RAS through reactive oxygen speciesinduced DNA damage and DNA hyperreplication (Di Micco et al., 2006) , oncogene-induced senescence is an important mode of tumor suppression, which blocks aberrant proliferative signals. Mounting evidence have suggested cooperation between RUNX proteins and RAS pathways during tumorigenesis: concurrent mutations in RUNX1 and RAS pathways are extremely frequent in RUNX1-related leukemia cases; Runx1 deficiency suppresses N-RAS-induced senescence and apoptosis, most likely through upregulation of Bmi-1 and Bcl-2 and consequent suppression of p16
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Arf expression (Motoda et al., 2007) ; RUNX3, similar to other RUNX family members, functions as a mediator of oncogene-induced senescence: it induces a p14 ARF -p53-dependent growth arrest in primary mouse embryonic fibroblasts that is reminiscent of senescence (Kilbey et al., 2007 . Future studies may reveal the degree to which RUNX family members are biologically linked to senescence.
Inter-relationship of RUNX3 with other RUNX family members
The strong conservation in amino-acid sequences of all RUNX family members suggests shared propertiesthey recognize the same DNA sequence-and some functional redundancy. Their differential expression profiles in various tissues, however, indicate that RUNX proteins have distinct biological functions, depending on cell context. Although RUNX proteins do co-exist in some cells, inverse correlation of RUNX3 and RUNX1 expression levels were observed in lymphoblastoid cell lines (Levanon et al., 1994; Spender et al., 2005) : RUNX3 protein represses the RUNX1 P1 promoter through its C-terminal VWRPY amino-acid motif, likely in collaboration with TLE co-repressors (Spender et al., 2005; . Moreover, this coordination of RUNX1 and RUNX3 levels is related to cell proliferation, in which RUNX3-mediated repression of RUNX1 promotes Epstein-Barr virus-induced immortalization of B cells . It would seem that RUNX3 and RUNX1 serves contradictory functions: growth promoter and inhibitor, respectively. But how does this relate to solid tumors? Inverse correlation between RUNX3 and RUNX2 expression was recently observed in some breast cancer cell lines in which cells with low RUNX3 expression show increased RUNX2 expression (Lau et al., 2006) . As all RUNX proteins are closely associated with cancer development, this communication between family members has important implications: dysfunctional RUNX3 would affect RUNX1 and RUNX2 activities on cell proliferation.
Oncogenic potential of RUNX3
Paradoxically, similar to other members of the RUNX family, RUNX3 can also function as an oncogene when overexpressed (Cameron and Neil, 2004) . Strong evidence from murine retroviral insertional work (see above) is now corroborated with findings from clinical samples and cancer cell lines. Immunohistochemical studies showed intense nuclear RUNX3 staining patterns in basal cell carcinoma tissues . Moreover, RUNX3 protein is overexpressed in epithelial ovarian cancer. However, immunohistochemical staining revealed a striking difference-the upregulated RUNX3 in ovarian cancer is cytoplasmic (Nevadunsky et al., 2009) . Reintroduction of RUNX3 in ovarian cancer cells led to increased viability, whereas depletion of RUNX3 resulted in reduced proliferation (Nevadunsky et al., 2009) . RUNX3 also has an oncogenic function in head and neck squamous cell carcinoma in which RUNX3 expression was correlated with enhanced cell proliferation and malignancy (Tsunematsu et al., 2009) . Interestingly, ectopic RUNX3 expression inhibited chemotherapeutic drug adriamycin-induced apoptosis in head and neck squamous cell carcinoma cells, reminiscent of the RUNX3-induced resistance to imatinib-induced apoptosis in chronic myeloid leukemia (Miething et al., 2007; Tsunematsu et al., 2009) . Thus, although RUNX3 is more commonly observed to suppress tumor formation, it has a dualistic function in cancer-whether it acts as tumor suppressor or oncogene is cell context dependent. How RUNX3 switches between such opposite activities remain unclear and is likely to be of great clinical relevance.
Conclusion
In this review, we have highlighted important findings that shape our current understanding of RUNX3 as a tumor suppressor (see Figure 2) . Multiple lines of evidence such as frequent inactivation of RUNX3 in cancer, its ability to interact with important components of various signaling pathways, and regulate their output-as seen by its enhancement of TGF-b-related growth inhibition and suppression of oncogenic Wnt activity-indicate that RUNX3 is closely linked to cancer pathogenesis and that aberrant activity of RUNX3 is a major determinant of cancer outcome. Furthermore, the rapidly expanding list of proteins that interacts with RUNX3 hints at involvement in other activities such as DNA damage response and repair. In time, a more complete knowledge of RUNX3's multiple properties and functions will offer important insights into the complex nature of tumor formation and allow exploitation of its effects during cancer therapy.
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